PharmaTimes | in-depth news, features and insights for the pharmaceutical and healthcare sectors

.tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end}[data-toolset-views-view-pagination-block="b5ee7a93952c82ad8154125da3a7733a"] ul { text-align: center;justify-content: center; } .tb-container .tb-container-inner{width:100%;margin:0 auto} .wp-block-toolset-blocks-container.tb-container[data-toolset-blocks-container="2c43613e993e2394568fe34903b86a0f"] { background:linear-gradient(rgba( 0, 0, 0, 0.13 ),rgba( 0, 0, 0, 0.13 )),   url('https://pharmatimes.com/wp-content/uploads/2023/12/AI.jpg') center center no-repeat;background-size:auto, cover;padding: 25px;min-height: 500px;display:ms-flexbox !important;display:flex !important;-ms-flex-direction:column;flex-direction:column;-ms-flex-pack:center;justify-content:center; } .tb-container .tb-container-inner{width:100%;margin:0 auto} .wp-block-toolset-blocks-container.tb-container[data-toolset-blocks-container="25729c831f4b8caf3a7382396af662f4"] { background: rgba( 110, 110, 110, 0.43 );padding: 15px 25px 15px 25px; } .tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em} .tb-button[data-toolset-blocks-button="37dad1b8a003c5dbbfa7f1938d6759a2"] .tb-button__link { background-color: rgba( 255, 255, 255, 0 );color: rgba( 255, 255, 255, 1 );border: 2px solid rgba( 255, 255, 255, 1 );font-weight: bold;color: rgba( 255, 255, 255, 1 ); } .tb-container .tb-container-inner{width:100%;margin:0 auto}h2.tb-heading[data-toolset-blocks-heading="3b7ed8e4afda9e2b6b6174785a4c06c4"]  { font-size: 42px;font-family: Merriweather;font-weight: bold;color: rgba( 255, 255, 255, 1 );text-align: left; }  @media only screen and (max-width: 781px) { .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end}.tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em}.tb-container .tb-container-inner{width:100%;margin:0 auto}  } @media only screen and (max-width: 599px) { .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end}.tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em}.tb-container .tb-container-inner{width:100%;margin:0 auto}  } 

Share the bill

What the NHS Modernisation Bill means for the life science...

News

IMAVVY approved as first targeted therapy for wAIHA

Sep 1, 2026

New treatment reduces pathogenic IgG while preserving B‑cell function

Nxera partner gains acceptance for NBI‑1117567

Sep 1, 2026

Phase 2 study to assess muscarinic M1 agonist in Alzheimer’s cognition

Jemperli accepted for priority review by US FDA

Aug 31, 2026

sBLA covers dMMR/MSI‑H stage II–III rectal cancer

Carterra supports AI‑designed protein study with HT-SPR platforms

Aug 31, 2026

Anthropic, twist and Adaptyv validate 1,320 binders across 15 targets

Erasca secures FDA fast track for eras‑0015 in pancreatic cancer

Aug 27, 2026

Designation supports rapid development of pan‑RAS molecular glue

Avulux gains FDA authorisation for migraine light‑sensitivity lens

Aug 27, 2026

New device classification created for precision optical filter

Web Exclusives

True colours

Jan 15, 2026

The gold standard in spectroscopy

Trust issues

Oct 24, 2025

Specialty pharmacies – a guide to regulatory bodies and standards

Leader of the packs

Oct 1, 2025

3 Packaging Companies that offer custom pharmaceutical packaging solutions

Fertile ground

Aug 24, 2025

Top-rated pharmacies in northern Virginia for personalised fertility care

Magazine

September 2026

Sep 1, 2026

This month’s mag takes the relentless tittle-tattle from ‘influencers’ about GLP-1 before scrutinizing, deconstructing and refining it in a way only we can! In that spirit, we ask: where have all the risk takers gone, why isn’t communication at the top table, and how do we make the most of data? As we bid farewell to a scorching summer, there’s still time to focus on the future of clinical trials and how pharma can navigate an exponentially changing NHS.